Dr. Gipson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
University of Michigan
Ann Arbor, MI 48109Phone+1 734-936-4210
Education & Training
- University of WashingtonFellowship, Pediatric Nephrology, 1995 - 1998
- Indiana University School of MedicineResidency, Pediatrics, 1989 - 1993
- Indiana University School of MedicineClass of 1989
- University of WashingtonMS, Epidemiology
Certifications & Licensure
- MI State Medical License 2009 - 2025
- NC State Medical License 1999 - 2010
- WA State Medical License 1993 - 1999
- American Board of Pediatrics Pediatric Nephrology
Clinical Trials
- Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS) Start of enrollment: 2005 Jul 01
- Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial Start of enrollment: 2008 Dec 01
- Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center Start of enrollment: 2009 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 117 citationsSCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease.Heejung Bang, Suma Vupputuri, David A. Shoham, Philip J. Klemmer, Ronald J. Falk
Archives of Internal Medicine. 2007-02-26 - 641 citationsUS Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States.Rajiv Saran, Bruce G. Robinson, Kevin C. Abbott, Lawrence Y. Agodoa, Jennifer L. Bragg-Gresham
American Journal of Kidney Diseases. 2019-03-01 - 565 citationsUS Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United StatesRajiv Saran, Bruce M. Robinson, Kevin C. Abbott, Jennifer L. Bragg-Gresham, Xiaoying Chen
American Journal of Kidney Diseases. 2020-01-01
Journal Articles
- DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGSHoward Trachtman, Peter Nelson, Abanti Chaudhuri, Jai Radhakrishnan, Olga Zhdanova, Debbie S Gipson, Tarak Srivastava, Kenneth Lieberman, Vimal Kumar Derebail, Jonatha..., Journal of the American Society of Nephrology
Authored Content
- US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United StatesFebruary 2018
Press Mentions
- CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular DiseaseNovember 10th, 2018
Grant Support
- FSGS Cohort StudyNational Institute Of Diabetes And Digestive And Kidney Diseases2010
- Multicenter Trial Of Focal GlomerulosclerosisNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2009
- Clinical Trial: Mycophenolate Mofetil In Patients With 1ga NephropathyNational Center For Research Resources2008
- Clinical Trial: Gc1008 In Patients With Treatment Resistant Idiopathic FSGSNational Center For Research Resources2008
- Clinical Trial: Focal Segmental Glomerulosclerosis Clinical TrialNational Center For Research Resources2008
- Novel Therapy For Resistant FSGSNational Center For Research Resources2007–2008
- Chronic Kidney Disease In ChildrenNational Center For Research Resources2006–2008
- Mycophenolate Mofetil In Patients With 1ga NephropathyNational Center For Research Resources2005–2007
- Focal Segmental Glomerulosclerosis Clinical TrialNational Center For Research Resources2005–2007
- Evaluation Of The Association Of Cognitive Function And Chronic Kidney DiseaseNational Center For Research Resources2005–2007
- Dialysis Adequacy In Children On Peritoneal DialysisNational Center For Research Resources1999–2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: